39 results about "Peanut food allergy" patented technology

The present disclosure relates to improved oral immunotherapy methods for treating food allergies, and particularly peanut allergy. Biomarkers, such as a level of peanut-specific IgE and/or peanut-specific IgG4s are used by the methods described herein. Such methods include a method of treating a subject for a peanut allergy, methods of assessing the suitability of a treatment for a peanut allergy, a method of evaluating a symptom in a subject during the course of treatment of a peanut allergy, a method of monitoring treatment for a peanut allergy in a subject, a method of reducing the risk or incidence of an adverse event in a subject receiving treatment for a peanut allergy, a method of adjusting a dose of an allergenic peanut composition, and a method of assessing a likelihood of an allergic reaction that requires administration of epinephrine to a subject receiving treatment for a peanut allergy.

The present invention provides compositions, systems, and methods for preventing and treating allergic reactions to peanut exposure. In certain embodiments, the present invention employs fusion proteins comprising a peanut allergen (or allergenic portion thereof), such as Ara h2, and an Fc protein (e.g., Fcγ1 protein), or functional portion thereof.

The invention discloses a building method and application of a recombinant lactococcus lactis for intracellular expression of a peanut allergen Arah2. A natural gene sequence of the peanut allergen Arah2 is subjected to codon optimization, so as to obtain an optimized gene nArah2, and a recombinant vector and lactococcus lactis engineering bacteria aiming at an intracellular expression mode of the nArah2 are built. A recombination strain disclosed by the invention is taken as an oral vaccine to immunize the mice, and the immunoreaction of mice anaphylaxis can be effectively regulated. Therefore, the recombinant lactococcus lactis can be developed as a mucosal vaccine to be applied to prevention and treatment of peanut allergy.

The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2mg, 5mg, 12.5mg, 25mg, 50mg, 0mg, 200mg, 400mg and 800mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years.

The invention provides a method for detecting an allergen in high oleic acid peanuts by using mass spectrometry. The method comprises the following steps: performing mass spectrometry on a high oleic acid peanut extract by using a mass spectrometry parallel reaction monitoring method to obtain protein information; comparing and screening the obtained protein information with bioinformatics data in a UniProt database to obtain the allergenic protein related to peanut allergy; and screening out a specific peptide fragment in the sensitization protein through a screening condition. The screening conditions comprise: 1) no modification; 2) the number of spectrums matching the amino acid sequence in the spectrum database is greater than 3; 3) the sequence only exists in one or two proteins; 4) the number of amino acids is 7 to 20; and 5) the peptide fragment does not contain cysteine and methionine. The method can be used for qualitatively and quantitatively detecting the peanut allergenic protein and is relatively high in accuracy; the protein and the peptide fragment can be confirmed, the corresponding peptide fragment can be specifically screened out, and a foundation is laid for subsequently detecting the peanut allergen by using an isotope dilution method.

Compositions and methods for the treatment of food allergies, particularly peanut allergy are provided. The compositions and methods are based on the observation that agents which interfere with the association of platelet activating fact (PAF) with its receptor (PAF-R) significantly reduce the severity and duration of anaphylaxis. Combination therapy with a PAF inhibitor and a histamine inhibitor provided an increased beneficial effect compared to treatment alone.

The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of peanut allergy in humans. Furthermore, the invention provides methods for preventing or treating of peanut allergy in humans.

Gastro-intestinal release capsule intended for oral use in a method for desensitizing and/or inducing tolerance in a peanut-allergic subject or, alternatively, for diagnosing a peanut allergy in a subject. The capsule has a shell and a core, the core has a composition of peanut including peanut, at least one oil, at least one first pulverulent excipient and, optionally, at least one second prebiotic excipient. The capsule is provided and ingested in an unopened form.

The present disclosure relates to methods of improving the quality of life of a subject having a peanut allergy. In certain embodiments, the disclosure provides methods for improving the quality of life of a subject having a peanut allergy by administering a peanut composition according to an oral immunotherapy schedule. In certain embodiments, the disclosure provides methods for improving the quality of life of a subject having a peanut allergy by informing the subject they are to be, or are being, administered a peanut composition according to an oral immunotherapy schedule.

Described herein are methods of assessing risk of a systemic allergic response in a subject being treated for a peanut allergy by an oral immunotherapy. The oral immunotherapy includes administering to the subject a composition comprising peanut protein according to an oral immunotherapy schedule comprising an up-dosing phase and a maintenance phase. The methods can include obtaining a peanut-specific IgE level when the subject tolerates the dose of 1000 mg or more peanut protein; and assessing the risk of a systemic allergenic response in the subject based on the obtained peanut-specific IgE level.